GoodRx (NASDAQ:GDRX) Major Shareholder Sells $1,666,071.75 in Stock

Key Points

• Francisco Partners sold 471,975 GoodRx shares for approximately $1.67 million at an average price of $3.53, reducing its position by 29.51% to 1.13 million shares. The shareholder also sold additional shares in separate transactions on August 20 and 21.
• GoodRx shares closed at $3.45, with the company valued at about $1.18 billion. The stock remains below its 52-week high of $5.81 but above its 52-week low of $1.77.
• GoodRx matched quarterly earnings expectations at $0.08 per share and exceeded revenue estimates with $200.41 million, although revenue declined 1.3% year over year. Analysts have a consensus “Hold” rating and an average price target of $4.23.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 471,975 shares of the business's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75. Following the completion of the sale, the insider owned 1,127,436 shares in the company, valued at $3,979,849.08. This represents a 29.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.

GoodRx Price Performance

Shares of NASDAQ:GDRX traded down $0.11 on Friday, reaching $3.45. The company's stock had a trading volume of 1,746,243 shares, compared to its average volume of 1,833,117. GoodRx Holdings, Inc. has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a market cap of $1.18 billion, a P/E ratio of 86.27, a PEG ratio of 1.77 and a beta of 1.60. The company has a 50-day simple moving average of $3.13 and a 200 day simple moving average of $2.63. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting analysts' consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. During the same period in the previous year, the firm posted $0.09 EPS. The business's quarterly revenue was down 1.3% on a year-over-year basis. As a group, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.16 EPS for the current fiscal year.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Essential Partners LLC grew its stake in shares of GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after buying an additional 11,295 shares during the last quarter. Meridian Wealth Management LLC bought a new stake in shares of GoodRx during the 4th quarter worth approximately $29,000. SG Americas Securities LLC bought a new position in GoodRx in the 1st quarter valued at $29,000. Headlands Technologies LLC purchased a new stake in GoodRx in the second quarter worth $30,000. Finally, Krilogy Financial LLC purchased a new stake in GoodRx in the first quarter worth $33,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GDRX has been the topic of a number of recent research reports. Wall Street Zen upgraded GoodRx from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Barclays lifted their target price on GoodRx from $3.00 to $4.00 and gave the stock an "underweight" rating in a report on Thursday. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, August 7th. The Goldman Sachs Group restated a "neutral" rating and set a $4.00 price target on shares of GoodRx in a report on Friday, August 7th. Finally, Citigroup raised their price target on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, GoodRx currently has an average rating of "Hold" and a consensus target price of $4.23.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source